IL6 and cancer: Moreover, resistance to VEGFR TKI treatment can lead to cellular changes resembling senescence-associated secretory phenotypes (SASPs), promoting recurrence of tumor growth and cancer progression regulated by mTOR signaling and IL6 [19, 35].